Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Recommendations for the optimal management of early and advanced urothelial carcinoma.

Castellano D, Carles J, Esteban E, Trigo JM, Climent MÁ, Maroto JP, del Muro XG, Font A, Paz-Ares L, Arranz JÁ, Bellmunt J.

Cancer Treat Rev. 2012 Aug;38(5):431-41. doi: 10.1016/j.ctrv.2011.10.004. Epub 2011 Nov 23. Review.

PMID:
22116017
2.

[European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract].

Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W; European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract.

Actas Urol Esp. 2012 Jan;36(1):2-14. doi: 10.1016/j.acuro.2011.09.001. Epub 2011 Oct 29. Spanish.

PMID:
22036956
3.

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS.

Urology. 2007 Jan;69(1 Suppl):62-79. Review.

PMID:
17280909
4.

[Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].

Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA; European Association of Urology.

Actas Urol Esp. 2010 Jan;34(1):51-62. Spanish.

PMID:
20223133
5.

Advanced bladder cancer in a young female: a case report.

Masuda A, Minakmi S, Usui Y, Arihara K, Nagata Y, Kawamura N.

Tokai J Exp Clin Med. 2001 Jul;26(2):39-43.

PMID:
11806441
6.

[Update on chemotherapy for bladder cancer. Update 2010].

Heck MM, Gschwend JE, Retz M.

Urologe A. 2010 Oct;49(10):1294-300. doi: 10.1007/s00120-010-2380-y. Review. German.

PMID:
20859610
7.

Diagnosis and management of superficial bladder cancer.

Amling CL.

Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. Review.

PMID:
11514784
8.

Low-grade Ta (noninvasive) urothelial carcinoma of the bladder.

Oosterlinck W, Solsona E, Akaza H, Busch C, Goebell PJ, Malmström PU, Ozen H, Sved P.

Urology. 2005 Dec;66(6 Suppl 1):75-89. Review.

PMID:
16399417
9.

Update on chemotherapy for advanced bladder cancer.

Rosenberg JE, Carroll PR, Small EJ.

J Urol. 2005 Jul;174(1):14-20. Review.

PMID:
15947569
10.

Selection of treatment for muscle infiltrating transitional cell bladder cancer.

Whitmore WF.

Arch Esp Urol. 1990;43 Suppl 2:219-22. Review.

PMID:
2096783
11.

Diagnosis and treatment of bladder cancer.

Sharma S, Ksheersagar P, Sharma P.

Am Fam Physician. 2009 Oct 1;80(7):717-23. Review.

12.

Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.

Izawa JI, Chin JL, Winquist E.

Can J Urol. 2006 Jun;13 Suppl 3:48-53. Review.

PMID:
16818012
13.

Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.

George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.

Urology. 2004 Sep;64(3):488-93. Review.

PMID:
15351577
14.

[Current developments in the diagnostics and therapy of bladder carcinoma].

Kamradt J, Ohlmann CH, Stöckle M.

Urologe A. 2011 Sep;50 Suppl 1:179-83. doi: 10.1007/s00120-011-2682-8. Review. German.

PMID:
21863408
15.

Management of bladder cancer: current and emerging strategies.

Agarwal N, Hussain M.

Drugs. 2009 Jun 18;69(9):1173-87. doi: 10.2165/00003495-200969090-00003. Review.

PMID:
19537835
16.

Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder.

Ghoneim IA, Miocinovic R, Stephenson AJ, Garcia JA, Gong MC, Campbell SC, Hansel DE, Fergany AF.

Urology. 2011 Apr;77(4):867-70. doi: 10.1016/j.urology.2010.11.043. Epub 2011 Feb 5.

PMID:
21296399
17.

Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.

Milowsky MI, Stadler WM, Bajorin DF.

BJU Int. 2008 Nov;102(9 Pt B):1339-44. doi: 10.1111/j.1464-410X.2008.07980.x. Review.

PMID:
19035902
18.

Impact of second opinion pathology in the definitive management of patients with bladder carcinoma.

Coblentz TR, Mills SE, Theodorescu D.

Cancer. 2001 Apr 1;91(7):1284-90.

PMID:
11283928
19.

Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.

Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford ED; Southwest Oncology Group Trial 8733.

Cancer. 2008 May 15;112(10):2181-7. doi: 10.1002/cncr.23420.

20.

Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer.

Calabrò F, Sternberg CN.

Eur Urol. 2009 Feb;55(2):348-58. doi: 10.1016/j.eururo.2008.10.016. Epub 2008 Oct 16. Review.

PMID:
18977070
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk